| Description | CPDA is a new potent inhibitor of SH2 domain-containing inositol phosphatase 2 (SHIP2). |
| In vitro | CPDA enhances insulin signaling. CPDA was found to enhance in vitro insulin signaling through the Akt pathway more efficiently than the previously reported SHIP2 inhibitor AS1949490, and ameliorated abnormal glucose metabolism in diabetic (db/db) mice. |
| In vivo | CPDA greatly improves abnormal glucose metabolism in diabetic animals. In db/db mice, CPDA improves abnormal glucose metabolism. |
| molecular weight | 388.8 |
| Molecular formula | C20H15ClF2N2O2 |
| CAS | 1415834-63-7 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 50 mg/mL (128.60 mM) |
| References | 1. Rational design and synthesis of 4-substituted 2-pyridin-2-ylamides with inhibitory effects on SH2 domain-containing inositol 5'-phosphatase 2 (SHIP2). Eur J Med Chem. 2013 Apr;62:649-660. |